Tong, T. M. L. http://orcid.org/0000-0002-7381-6858
Burgmans, M. C.
Speetjens, F. M.
van Erkel, A. R.
van der Meer, R. W.
van Rijswijk, C. S. P.
Jonker-Bos, M. A.
Roozen, C. F. M.
Sporrel-Blokland, M.
Lutjeboer, J.
van Persijn van Meerten, E. L.
Martini, C. H.
Zoethout, R. W. M.
Tijl, F. G. J.
Blank, C. U.
Kapiteijn, E.
Funding for this research was provided by:
Bristol-Myers Squibb
Delcath Systems Inc.
Article History
Received: 8 June 2022
Accepted: 6 December 2022
First Online: 9 January 2023
Declarations
:
: EK and MB have received consultancy fees from Delcath Systems. EK has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, and received research grants from Bristol Myers Squibb and Pierre Fabre. CB has an advisory role for MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures, receives research funding from BMS, Novartis, NanoString and 4SC, has stockownership in Immagene BV and a pending patent for WO 2021/177822 A1. The other authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Consent for publication was obtained for every individual person’s data included in the study.